Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
New Prime Editing and non-viral delivery strategies for Gene Therapy (EdiGenT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Challenges
Action type: EIC actions
Countries involved: France,Netherlands,Spain,Portugal
Call: Emerging Technologies in Cell and Gene therapy (HORIZON-EIC-2021-PATHFINDERCHALLENGES-01, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 4406097.5
EU funding (EUR): 4406097.5
Participants: 6
Project status: SIGNED

Genome editing technologies based on CRISPR/Cas systems allow targeted genomic modification with unprecedented precision and have emerged as powerful alternatives to the conventional gene therapy approaches for various human diseases, with a series of clinical trials in progress. However, some crucial challenges remain to be addressed to enhance efficiency and safety and decrease costs of treatments. Current viral-based delivery systems are associated with high risk of toxicity and immunogenicity and remain highly expensive. We will develop a new generation of non-viral delivery systems for gene editing tools based on the use of modified nanoparticles with human-derived protein moieties that will allow targeting the tissue and cells of interest in vivo with minimal adverse effects. Prime editors have raised exciting possibilities for double-strand break free genome editing. However, a major limitation of current prime editors is highly variable efficiency both from one target to another and between cell types. We will design and evaluate novel prime editor tools in order to both increase activity per se and overcome cell-specific limitations.We will test our approach on the hematopoietic system to treat Sickle Cell Disease, avoiding the challenges and risks of hematopoietic stem cell manipulation associated with current gene therapy approaches, and thus providing a treatment much simpler, safer and cost-effective to implement. Our technological breakthroughs address two key obstacles in cell and gene therapy: gene editing efficiency and systemic delivery. The novel prime editors and targeted nanoparticles that we will engineer will be combined to make unprecedented off-the-shelf, recombinant biologics for gene therapy. The versatility of the design of these novel recombinant biologics makes them suitable for the treatment of a vast majority of genetic diseases.

Keywords: prime editing,zebrafish,nanoparticles,rare monogenic disease
Asymmetric carbyne catalytic transfer to streamline synthesis of chiral β-amino carbonyls (Chiral-Beta)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Spain,Switzerland
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 181152.96
EU funding (EUR): 181152.96
Participants: 2
Project status: SIGNED

The chiral β-amino carbonyl is an important structural motif prevalent in natural products and therapeutic agents. Despite that many methodologies have been developed for their diastero- and enantioselective synthesis, most of these methods require multistep manipulations with pre-functionalized substrates that fail to introduce the β-amino carbonyl moiety at the late-stage of complex molecule synthesis. Chiral-Beta aims to develop an innovative technology to rapidly construct chiral β-amino carbonyl derivatives with feedstock and fine alkenes as well as with complex drug molecules/natural products based on a Rh-catalyzed asymmetric carbyne transfer platform. A key strength of this conceptually new and multidisciplinary proposal is the introduction of a secondment phase in Novartis (Basel) to explore real-life applications. The ambitious action merges perfectly the expertise of the host in novel C-H and C–C bond functionalization strategies based on the catalytic generation of carbyne equivalents with the strong background of the applicant in metal-catalyzed asymmetric reactions, thus enhancing two-way transfer of knowledge between the ER and the host group. This project will expose the fellow to a wide range of cutting-edge chemistry and biomedical sciences in an interdisciplinary and international environment (ICIQ, Novartis) and enable the fellow to become a leader for the next generation in the field of chemical synthesis and late-stage functionalization techniques.

Keywords: rh carbenes,hypervalent iodine reagents,c c bond cleavage,amination,beta amino carbonyls
Electroanatomical exploration of pulmonary veins sleeve myocardium in the development of atrial fibrillation in ageing and hypertension (MaPViAH)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark,United Kingdom
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-04-01
End date: 2026-03-31
Duration (months): 24.0
Total project cost (EUR): 230774.4
EU funding (EUR): 230774.4
Participants: 2
Project status: SIGNED

In mammals, the complex anatomical structure connecting pulmonary veins (PVs) with the posterior wall of the left atrium (LA) of the heart, defined as LA-PV junction, is a source of electrical ectopic pulses, which initiate and maintain atrial fibrillation (AF), the most prominent sustained arrhythmia that worsens with tissue remodelling due to ageing and hypertension. PVs’ resident cardiomyocytes generate electrical pulses contributing to arrhythmogenesis within the LA-PV junction. Moreover, “PV myocardium” expresses atrial-specific small conductance calcium-activated potassium (SK) channels, which are involved in AF. Although PVs ectopy is pivotal in AF onset, the pathophysiological space-time dynamic of PV cardiomyocytes’ intermittent firing and the proarrhythmic role of SK-channels in the LA-PV junction have not been investigated in ageing and hypertension. Aim of this project is to define and quantify, for the first time, the intermittent arrhythmogenic pattern of pulses generated by PV cardiomyocytes when challenged by SK-channels antagonists in young adult and aged spontaneously hypertensive rats compared to age-matched healthy rats. Moreover, the three-dimensional electrical heterogeneity of LA-PV spontaneous firing will be described by creating electro-anatomical high-density maps in the aforementioned experimental groups. This project will generate critical knowledge about how LA-PV junction electrically dissociates from sinus rhythm during AF onset and will unveil the role of PVs’ SK-channels in the pathophysiology process of AF. Moreover, this will allow me to acquire new skills to become a successful independent researcher in cardiovascular physiology and electrophysiology of cardiac arrhythmias.

Keywords: pulmonary veins atrial fibrillation sk channels cardiac arrhythmias electrophysiology ageing hypertension
Versi Bionics robotic bionic prosthesis (VERSI BIONICS)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Ukraine
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 4100000.0
EU funding (EUR): 4100000.0
Participants: 1
Project status: SIGNED

This proposal presents a breakthrough innovation in the field of medical technology: the Versi Bionics bionic hand prosthesis. The product utilizes advanced artificial intelligence technologies and feedback sensors to improve the quality of life for people with amputations. The primary goal of the project is to provide accessible and highly functional prosthetic solutions capable of radically transforming the rehabilitation and recovery of motor functions for users in Europe, the USA, and Ukraine. The breakthrough nature of Versi Bionics is evident in several key aspects: 1. Adaptive Capabilities: The integration of artificial intelligence allows the prosthesis to adapt to the individual needs of the user, providing a unique level of control and precision. 2. Modular Design: A revolutionary design that enables easy replacement of components, enhancing convenience in use and maintenance. 3. Innovative Tactile System: The use of feedback sensors provides realistic sensations of touch, temperature, and pressure, significantly improving the functionality and comfort of the user. The significance of the project for the HORIZON-EIC-2024-ACCELERATOR program lies in its support for the development of advanced

Keywords: robotic,robotic bionic,health,medicine
SEAMLESS SHARED URBAN MOBILITY (SUM)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Mobility
Destination: Safe, Resilient Transport and Smart Mobility services for passengers and goods
Action type: Innovation actions
Countries involved: France,Belgium,Germany,Greece,Israel,Netherlands,Poland,Cyprus,Spain,Norway,Sweden,Portugal,Switzerland
Call: Accelerating the deployment of new and shared mobility services for the next decade (HORIZON-CL5-2022-D6-02, 2022)
Start date: 2023-06-01
End date: 2026-05-31
Duration (months): 36.0
Total project cost (EUR): 10760895.0
EU funding (EUR): 9872097.75
Participants: 30
Project status: SIGNED

The objective of SUM is to transform current mobility networks towards innovative and novel shared mobility systems (NSM) integrated with public transport (PT) in more than 15 European Cities by 2026 reaching 30 by 2030. Intermodality, interconnectivity, sustainability, safety, and resilience are at the core of this innovation. The outcomes of the project offer affordable and reliable solutions considering the needs of all stakeholders such as end users, private companies, public urban authorities. SUM project will develop five pillars consisting of technological, co-creation, and policy tools to tackle the identified NSM barriers for a typical, car-focused family. These five pillars can increase the modal share of NSM via targeted push/pull measures and policy recommendations. SUM will introduce a federation of solutions including prediction, scheduling, integrated NSM-PT ticketing, and real-time NSM management. This created ecosystem will reduce the total door-to-door travel times using integrated NSM-PT. This can change the behavior of 34% of travelers using cars and 17% of travelers sceptic about using NSM. The partners in this diverse consortium have access to innovative tools and expertise making them uniquely positioned to tackle the barriers in 9 living labs and 30 organizations across Europe.
Primary Sector Working Group Support Project (RootLinks)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Public-private partnerships
Destination: Circular Bio-based Europe
Action type: Coordination and support actions
Partnership: CBE (JU-JTI)
Countries involved: Germany,Spain,Finland,Italy,Austria,Czechia,Malta,Slovakia
Call: Supporting the CBE JU Deployment Group on Primary Producers (HORIZON-JU-CBE-2024, 2024)
Start date: 2025-04-01
End date: 2029-03-31
Duration (months): 48.0
Total project cost (EUR): 2999661.25
EU funding (EUR): 2999661.25
Participants: 9
Project status: SIGNED

Engaging primary producers (PP) in RDI programs remains a significant challenge across Europe. This challenge is driven by factors such as limited access to information, low awareness of bio-based solutions, and various structural, financial, and regulatory barriers. These obstacles hinder PP integration into emerging circular bio-based value chains, despite the potential to introduce new business models that offer environmental benefits, including energy and nutrient recycling, sustainable production systems, and new revenue streams in rural areas. The CBE JU is committed to enhancing the involvement of primary producers within its funding schemes and the resulting innovative solutions. To this end, a Working Group on Primary Producers (WGPP) will be established, bringing together sector representatives from agriculture, forestry, and the blue economy. This group will develop an Action Plan aimed at strengthening the role of PPs in future CBE JU-funded projects and beyond. RootLinks will support and facilitate the efforts of the WGPP in co-creating and implementing this Action Plan. It includes horizontal and sector-specific actions designed to improve the role of primary producers in CBE JU programming, increase their participation in calls, and enhance their ability to exploit new value chains. The focus will be on to generate direct, tangible, and measurable benefits for PP, empowering them to become strong partners in cross-disciplinary bio-based research and innovation projects across Europe. Furthermore, RootLinks actions will enhance the roles of PP in exploiting innovations and related value chains, fostering improved collaboration between PPs and the bio-based industry. RootLinks offers a unique portfolio of sector expertise and competencies, implementing a comprehensive set of activities at the European, national, and regional levels, including knowledge and awareness-raising, capacity building and training, partnership development, and networking.

Keywords: primary producers agriculture,forestry,blue bioeconomy
MagMech: Precision magnetic tweezers for the mechanobiology of cells and tissues. (MagMech)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: France
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-09-01
End date: 2024-02-29
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 2
Project status: CLOSED

The mechanobiology of cells and tissues plays an essential role in physiology and diseases. This emerging field at the frontier between physics, engineering and biology, heavily relies on precise and versatile devices to apply and measure mechanical forces within and around cells and tissues. However the current commercial landscape is restricted to few systems that are limited to a small range of forces and poorly compatible with large tissues and embryos. In the FORCASTER ERC Consolidator project, our team invented a magnetic tweezer system which allows to apply large calibrated forces on magnetic particles embedded within cells and tissues, or at their surface, which largely overcome the limits of the current commercially available devices. In the MagMech PoC we will: (i) perform key technological updates to improve the versatility, stability and precision of the device; (ii) Gather proof of concept data in multiple relevant tissues, organs and embryos to support its broad potential for studying the mechanobiology of cells and tissues in a variety of physiological and disease contexts and; (iii) Starting from the recent filling of a patent, perform market evaluations, including KOLs and end-users interviews, establish partnerships with different industrial sectors, as well as consider the creation of a start-up to support the commercialization of this technology in the near future. With this PoC project, we will thus assess the value proposition that the magnetic tweezer system developed in FORCASTER ERC project can be brought to the market, serving as a key alternative to the existing commercial systems, for applying and measuring forces within and around cells and tissues.
The natural K, Fe, and Cu isotopic response to Pt-based chemotherapeutic drug resistance in ovarian cancer (CROC)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-09-01
End date: 2026-08-31
Duration (months): 24.0
Total project cost (EUR): 175920.0
EU funding (EUR): 175920.0
Participants: 1
Project status: SIGNED

Cancer is the second leading cause of death globally and in the EU, and was responsible for an estimated one in six deaths in 2018. Early diagnosis plays an important role in determining cancer treatment outcomes, but the diagnosis of ovarian cancer poses significant challenges; the routine screening of asymptomatic average-risk women is not recommended by any professional society. Chemotherapy using Pt-based compounds (e.g. carboplatin, cisplatin) is a standard treatment, but tumours that are initially responsive may develop chemoresistance, resulting in treatment failure. The ability to predict patient response towards post-operative treatments would allow for ineffective treatments and harmful side effects to be avoided and alternative treatments to be commenced at earlier stages. Several mechanisms underlying tumour cell resistance have been identified so far, including the altered expression of ion channels (Na, Mg, K, and Ca) and Fe-, Cu-, and Zn-binding proteins, but these remain poorly understood and it is unclear whether they can be exploited as markers of resistance. To that end, I will apply high-precision isotopic analysis by multicollector-inductively coupled plasma-mass spectrometry to Fe, K, and Cu to understand processes and determine whether changes in the natural abundances of these isotopes are associated with the development of resistance to Pt-based chemotherapeutic drugs in high-grade serous ovarian cancer (HGSOC), the deadliest gynaecological cancer, which accounts for ~70% of ovarian malignancies. Deviations in natural isotopic abundances signal biochemical changes (affecting the extent of isotopic fractionation accompanying some biochemical processes) occurring as a result of a disease in a systematic and reliable way. Through ovarian cancer cell line, tumour spheroid, and HGSOC patient plasma experiments, I aim to develop a revolutionary, minimally-invasive prognostic marker of Pt-based chemotherapeutic drug resistance.

Keywords: ovarian cancer,hgsoc,isotopic analysis,chromatography,metal homeostasis,mc icp ms
Unconventional Crafting of Chiral Aza-compounds using Visible Light Photocatalysis (ChirAzaL)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Italy
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-07-01
End date: 2025-06-30
Duration (months): 24.0
Total project cost (EUR): 188590.08
EU funding (EUR): 188590.08
Participants: 1
Project status: CLOSED

The aim of ChirAzaL is to devise innovative and sustainable technologies in organic synthesis to access general, modular, and scalable crafting of two families of biologically relevant chiral nitrogen-containing molecules, namely: azetidines and multisubstituted linear amines. Such molecules are characterized by a complex three-dimensional arrangement and a high degree of saturation. Harnessing visible-light as sustainable and unexpensive source of energy, I will use a strain-release approach to access these synthetically complex scaffolds. Asymmetric phase transfer catalysis and chiral-metal templated catalysis will be the foundation of this proposal for securing stereocontrol. In order to accomplish the overarching goal of the research program, it will be divided into two main stages: an exploratory Stage I, followed by the consequently more applicative Stage II. The application of the developed photocatalyzed transformations in flow technology will unlock a new and operational-friendly pathway to azetidines and multisubstituted linear amines under mild and efficient conditions. Lastly, the implementation of the developed chemistry, as a functionalization tool, will give access to a straightforward methodology which has serious potential to be embraced on any synthetic route. The multidisciplinary skills acquired due to the interaction between the two phases, together with the transfer of knowledge between me and the hosting group will guarantee the successful realization of ChirAzaL.

Keywords: chirality,nitrogen,heterocycle,strain,drug discovery
Bridging the digital divide and addressing the need of Rural Communities with Cost-effective and Environmental-Friendly Connectivity Solutions (COMMECT)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Resilient, inclusive, healthy and green rural, coastal and urban communities
Action type: Research and Innovation actions
Countries involved: Luxembourg,Denmark,Norway,Netherlands,Finland,Türkiye,Serbia,Ireland,France,Germany
Call: Smart XG, last-mile and edge solutions for remote farming, forestry and rural areas (HORIZON-CL6-2021-COMMUNITIES-01, 2021)
Start date: 2022-09-01
End date: 2025-08-31
Duration (months): 36.0
Total project cost (EUR): 4999558.75
EU funding (EUR): 4999558.75
Participants: 21
Project status: SIGNED

Over the last years, the importance and need for broadband and high-speed connectivity has constantly increased. The Covid-19 pandemic has even accelerated this process towards a more connected society. But this holds mainly true for urban communities. In Europe a 13% lack access still persists, and mainly concerns the most rural and remote areas. Those are the most challenging to address since they are the least commercially attractive. COMMECT aims at bridging the digital divide, by providing quality, reliable, and secure access for all in rural and remote areas. The goal of extending broadband connectivity in rural and remote areas will be achieved by integrating Non-Terrestrial Networks with terrestrial cellular XG networks, and low-cost Internet of Things (IoT). Artificial Intelligence, Edge and Network Automation will reduce energy consumption both at connectivity and computing level. Participatory approach with end-users and ICT experts working together on development challenges will be the key for the digitalization of the sector. To ensure the rich exchange of best-practice and technical knowledge among the actors of the agro-forest value chain, COMMECT will set up five Living Labs across and outside Europe, where end-users “pain” and (connectivity) “gains” will be largely discussed, from different perspectives. COMMECT aims at contributing to a balanced territorial development of the EU’s rural areas and their communities by making smart agriculture and forest services accessible to all. COMMECT will facilitate that, by developing a decision-making support tool able to advise on the best connectivity solution, according to technical, socio-economic, and environmental considerations. This tool, incorporating collaborative business models, will be a key enabler for jobs, business, and investment in rural areas, as well as for improving the quality of life in areas such as healthcare, education, e-government, among others.

Keywords: xg,edge,iot,ai,broadband connectivity,satellite,business models,environmental impact,socio economic impact,decision making support tool